{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/67c1df0d5c185beda428a6a2?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"AI Models Writing DNA and Designing Enzymes, Some Pre-AGBT News","description":"<p>In honor of Rare Disease Day, we discuss news from Healx, a clinical-stage biotech, which has dosed the first patient in a Phase II trial of its new drug for neurofibromatosis type 1. In the world of AI, the Arc Institute in collaboration with Nvidia has dropped Evo 2, the “largest publicly accessible AI model for biology to date,” for designing genomes. Additionally, new work from Nobel Laureate, David Baker, uses AI to generate enzymes from scratch. We also dig into the big announcements from Illumina and Roche that got the community buzzing ahead of this year’s AGBT meeting. </p><p><br></p><p>Join <em>GEN</em> editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.</p><p>&nbsp;</p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>:</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/healx-candidate-springworks-therapy-expand-nf1-treatment-options/\" rel=\"noopener noreferrer\" target=\"_blank\">Healx Candidate, SpringWorks Therapy Expand NF1 Treatment Options</a></p><p>By Alex Philippidis, <em>GEN Edge</em>, February 25, 2025</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/genome-editing/arc-institutes-ai-model-designs-the-genetic-code-across-all-domains-of-life/\" rel=\"noopener noreferrer\" target=\"_blank\">Arc Institute’s AI Model Evo 2 Designs the Genetic Code Across All Domains of Life</a> </p><p>By Fay Lin, PhD, <em>GEN Edge</em>, February 19, 2025</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/artificial-intelligence/ai-driven-protein-design-produces-enzyme-that-mimics-natural-hydrolase-activity/\" rel=\"noopener noreferrer\" target=\"_blank\">AI-Driven Protein Design Produces Enzyme that Mimics Natural Hydrolase Activity</a> </p><p>By Corinna Singleman, PhD,<em> GEN</em>, February 13, 2025</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/omics/illumina-unveils-spatial-technology-days-before-agbt-meeting/\" rel=\"noopener noreferrer\" target=\"_blank\">Illumina Unveils Spatial Technology Days Before AGBT Meeting</a> </p><p>By Julianna LeMieux, PhD, <em>GEN</em>, February 19, 2025</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/omics/stockwatch-illumina-tumbles-on-q4-results-china-retaliation/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: Illumina Tumbles on Q4 Results, China Retaliation</a> </p><p>By Alex Philippidis, <em>GEN Edge</em>, February 8, 2025</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/omics/roche-announces-sbx-technology-creates-sequencing-buzz/\" rel=\"noopener noreferrer\" target=\"_blank\">Roche Announces SBX Technology, Creates Sequencing Buzz</a> </p><p>By Julianna LeMieux, PhD, <em>GEN</em>, February 21, 2025</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/omics/stockwatch-nih-indirect-cost-cuts-shake-tools-stocks/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: NIH Indirect Cost Cuts Shake Tools Stocks</a>&nbsp;</p><p>By Alex Philippidis, <em>GEN Edge</em>, February 17, 2025</p><p><strong>&nbsp;</strong></p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}